Evidence map›Paper›PMID 37150944›Full record

ArticleEpilepsia2023

Characterizing the treatment gap in the United States among adult patients with a new diagnosis of epilepsy.

Barbara M Decker, Colin A Ellis, Emily Schriver, Kelly Fischbein, Debbie Smith, Jason T Moyer, Catherine V Kulick-Soper, Danielle Mowery, Brian Litt, Chloe E Hill

Open access · hybridAbstract read
In one paragraph

Article in Epilepsia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Primary treatment gap among adults with epilepsy: A cross-sectional analysis.Epileptic disorders : international epilepsy journal with videotape · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Barbara M DeckerDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0002-8084-7353
Colin A EllisDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-2152-8106
Emily SchriverData Analytics Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kelly FischbeinUCB Pharma, Smyrna, Georgia, USA.
Debbie SmithUCB Pharma, Smyrna, Georgia, USA.
Jason T MoyerUCB Pharma, Smyrna, Georgia, USA.
Catherine V Kulick-SoperDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Danielle MoweryDepartment of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Brian LittDepartment of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-2732-6927
Chloe E HillDepartment of Neurology, University of Michigan, Ann Arbor, Michigan, USA.ORCID 0000-0001-5307-4167
UCB Pharma (United States) · USUniversity of Pennsylvania · USPenn Center for AIDS Research · USUniversity of Michigan · USUniversity of Vermont Medical Center · US

Funding

Institutional Career Development CoreKL2TR002241 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELLINGROD, VICKI L · 2017 to 2021
$6.9M
Ghost in the Machine: Melding Brain, Computer and BehaviorDP1NS122038 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI LITT, BRIAN · 2020 to 2024
$5.7M
Neurologic Clinical Epidemiology Training ProgramT32NS061779 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Andrea Lauren Christman Schneider, Allison Willis · 2008 to 2026
$4.6M
Training Program in Neuroengineering and MedicineT32NS091006 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Brian Litt · 2015 to 2026
$4.1M
Polygenic risk in familial epilepsyK23NS121520 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ELLIS, COLIN · 2021 to 2025
$1.1M
Optimizing Care for Patients with Drug-Resistant EpilepsyK23NS126495 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Chloe E Hill · 2023 to 2026
$881k
NCATS NIH HHS KL2 TR002241NIH HHS 1DP1 NS122038-01NIH HHS K23NS121520NIH HHS K23NS126495NIH HHS KL2TR002241NINDS NIH HHS DP1 NS122038NINDS NIH HHS K23 NS121520NINDS NIH HHS K23 NS126495NINDS NIH HHS T32 NS061779NINDS NIH HHS T32 NS091006
6 · The paper itself

Abstract

objectiveEpilepsy is largely a treatable condition with antiseizure medication (ASM). Recent national administrative claims data suggest one third of newly diagnosed adult epilepsy patients remain untreated 3 years after diagnosis. We aimed to quantify and characterize this treatment gap within a large US academic health system leveraging the electronic health record for enriched clinical detail.

methodsThis retrospective cohort study evaluated the proportion of adult patients in the health system from 2012 to 2020 who remained untreated 3 years after initial epilepsy diagnosis. To identify incident epilepsy, we applied validated administrative health data criteria of two encounters for epilepsy/seizures and/or convulsions, and we required no ASM prescription preceding the first encounter. Engagement with the health system at least 2 years before and at least 3 years after diagnosis was required. Among subjects who met administrative data diagnosis criteria, we manually reviewed medical records for a subset of 240 subjects to verify epilepsy diagnosis, confirm treatment status, and elucidate reason for nontreatment. These results were applied to estimate the proportion of the full cohort with untreated epilepsy.

resultsOf 831 patients who were automatically classified as having incident epilepsy by inclusion criteria, 80 (10%) remained untreated 3 years after incident epilepsy diagnosis. Manual chart review of incident epilepsy classification revealed only 33% (78/240) had true incident epilepsy. We found untreated patients were more frequently misclassified (p < .001). Using corrected counts, we extrapolated to the full cohort (831) and estimated <1%-3% had true untreated epilepsy. SIGNIFICANCE: We found a substantially lower proportion of patients with newly diagnosed epilepsy remained untreated compared to previous estimates from administrative data analysis. Manual chart review revealed patients were frequently misclassified as having incident epilepsy, particularly patients who were not treated with an ASM. Administrative data analyses utilizing only diagnosis codes may misclassify patients as having incident epilepsy.

Indexed as

AnticonvulsantsEpilepsyAdultElectronic Health RecordsHumansRetrospective StudiesSeizuresUnited StatesAnticonvulsantsepidemiologyepilepsyhealth services researchtreatment gap

Identifiers

PMID37150944
PMCPMC10524597
OpenAlexW4375855591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.